Allergy: Understanding the Causes, Symptoms, and Treatment Options

Allergies are among the most common chronic health conditions in the world, affecting roughly one in three adults and more than one in four children in the United States alone — numbers that have been rising steadily in industrialized countries over the past several decades. Yet for something so prevalent, the underlying biology is widely misunderstood, and the range of available treatments is broader than most people with allergies realize.

This article explains what actually happens during an allergic reaction, why the immune system behaves this way, what the different types of allergies involve, how diagnosis works, and what the evidence supports across the full treatment spectrum — from over-the-counter antihistamines to prescription biologics.

What Happens During an Allergic Reaction

An allergy is, at its core, a case of mistaken identity. The immune system — whose job is to identify and neutralize genuinely harmful invaders — misidentifies an ordinarily harmless substance as a threat and mounts a defense response against it. That harmless-but-misidentified substance is the allergen. The immune response it triggers is what produces allergy symptoms.

The mechanism involves a class of antibodies called immunoglobulin E, or IgE. On first exposure to a new allergen, the immune system in sensitized individuals produces IgE antibodies specific to that allergen and attaches them to mast cells (found throughout body tissues) and basophils (found in the blood). This first exposure typically produces no noticeable symptoms — it's a setup phase called sensitization.

On subsequent exposures, the allergen binds to the IgE antibodies already coating those mast cells. This cross-linking triggers the cells to rapidly degranulate — releasing a cascade of inflammatory chemicals including histamine, leukotrienes, cytokines, and prostaglandins. These mediators cause the characteristic effects: vasodilation (causing flushing and swelling), increased mucus secretion (causing runny nose and congestion), smooth muscle contraction (causing bronchospasm and wheezing), and nerve stimulation (causing itching). The entire sequence from exposure to symptoms can occur within minutes.

This IgE-mediated process covers the most common forms of allergy — hay fever, food allergy, pet allergy, insect venom allergy — and is classified as Type I hypersensitivity. Contact dermatitis, by contrast, involves a different arm of the immune system (T cells rather than antibodies) and is classified as Type IV hypersensitivity, which is why it presents differently and responds to different treatments.

Types of Allergies and Their Triggers

Allergic conditions vary significantly depending on what triggers them and where in the body the reaction occurs.

Allergic rhinitis (hay fever) is the most prevalent allergic condition, affecting approximately 20% of people in developed countries. Triggers are typically airborne allergens: pollen from trees, grasses, and weeds (which produce seasonal symptoms), and year-round triggers including dust mites, pet dander, cockroach particles, and mold spores. Symptoms concentrate in the upper respiratory tract and eyes — sneezing, congestion, runny nose, itching, and watery eyes.

Food allergies are estimated to affect about 10% of adults and 8% of children in the United States. A striking 90% of food allergy reactions are caused by just eight foods: cow's milk, eggs, peanuts, tree nuts, fish, shellfish, wheat, and soy. Peanut and tree nut allergies tend to be lifelong in most people, while milk and egg allergies are more commonly outgrown in childhood. Food allergy reactions range from localized oral tingling (oral allergy syndrome) to hives, gastrointestinal distress, and — in serious cases — anaphylaxis.

Atopic dermatitis (eczema) is a chronic inflammatory skin condition with a strong allergic component that affects approximately 20% of people at some point. It involves a dysfunctional skin barrier and immune dysregulation, and frequently co-occurs with asthma and allergic rhinitis — a cluster of conditions that often appear together and is known as the atopic march.

Allergic asthma is a form of asthma triggered or worsened by allergen exposure, involving airway inflammation and bronchospasm. Drug allergies most commonly involve penicillin and related antibiotics, sulfa drugs, and NSAIDs, and typically present as skin rashes, though severe drug reactions can be systemic. Insect venom allergy — particularly from bees, wasps, and hornets — affects a small percentage of the population but carries a meaningful risk of anaphylaxis.

Who Gets Allergies and Why Rates Are Rising

Allergic conditions have a strong genetic component — people with one allergic parent have roughly a 30–50% chance of developing some form of allergy, and those with two allergic parents have an even higher risk. But genetics alone doesn't explain why allergy rates have been rising in developed countries over the past several decades while remaining much lower in less industrialized settings. That pattern has driven substantial research into environmental and lifestyle explanations.

The hygiene hypothesis — first proposed in 1989 — suggests that reduced childhood exposure to infections and microbial diversity in hygienic modern environments may prevent the immune system from properly calibrating itself, leaving it prone to overreacting to harmless environmental substances. More recent refinements focus specifically on the gut and respiratory microbiome: the microbial ecosystems that colonize the body during early life may be critical for training appropriate immune tolerance.

Factors associated with rising allergy rates in industrialized societies include increased antibiotic use (which disrupts microbial diversity), C-section births (which reduce neonatal microbial exposure), reduced time spent in natural environments, dietary changes including reduced fiber intake that affects gut microbiome composition, and air pollution (which can enhance allergenicity of pollen and increase airway inflammation). Vitamin D deficiency has also been proposed as a contributing factor, given vitamin D's role in immune regulation and its correlation with allergy rates across geographic regions.

The same interconnection between systemic inflammation, lifestyle factors, and immune function that underlies allergy susceptibility also appears in other chronic conditions, which is why the foundational health practices that support immune regulation — diet quality, sleep, stress management, and microbiome-supporting behaviors — consistently matter across a range of conditions, as explored in examinations of what evidence-based healthy living actually involves.

Diagnosing Allergies: What the Tests Actually Measure

Allergy diagnosis begins with a clinical history — documenting what symptoms occur, when and where they appear, what exposures precede them, and what provides relief. A detailed history is often the most informative diagnostic step. Testing then provides objective confirmation and helps identify specific triggers.

Skin prick testing is the most commonly used method. Tiny amounts of standardized allergen extracts are introduced into the skin via small punctures, and the site is observed for 15–20 minutes. A wheal (raised bump) and flare (surrounding redness) of 3mm or more beyond the negative control indicates sensitization to that allergen. Skin prick testing is rapid, relatively inexpensive, and can test many allergens simultaneously, but requires stopping antihistamines beforehand and carries a small risk of systemic reaction in highly sensitive individuals.

Specific IgE blood testing (including the ImmunoCAP platform) measures the concentration of allergen-specific IgE antibodies in blood. It doesn't require stopping medications and is safer for people with severe reactions or problematic skin conditions. Higher specific IgE levels correlate with greater likelihood of clinical allergy, but sensitization — having specific IgE — doesn't guarantee clinical reactivity. A positive test means the immune system has recognized the allergen; it doesn't automatically mean the person will have symptoms on exposure. For food allergies especially, the correlation between IgE levels and symptom severity is imperfect.

Oral food challenges — controlled, medically supervised ingestion of a suspected food allergen — are considered the gold standard for diagnosing food allergy when tests give ambiguous results or when determining whether a childhood allergy has been outgrown. They are typically done in a clinical setting given the risk of reaction.

Patch testing uses a different process — allergen patches applied to the skin for 48 hours — to diagnose Type IV (T-cell mediated) contact dermatitis reactions such as those from nickel, fragrances, or preservatives in personal care products.

Treatment: Medications

Most allergy management involves some combination of allergen avoidance and medication. Medications address the symptoms of allergic reactions without modifying the underlying immune response, which is why they must be taken continuously to provide ongoing benefit.

Antihistamines block the action of histamine at H1 receptors and are the most widely used allergy medications. First-generation antihistamines (diphenhydramine — the active ingredient in Benadryl) are effective but cross the blood-brain barrier, causing sedation and impaired cognition that makes them inappropriate for regular daytime use and dangerous for driving or operating machinery. Second-generation antihistamines (cetirizine, fexofenadine, loratadine) have much lower CNS penetration, are non-sedating at standard doses in most people, and are considered first-line for ongoing allergy management. They work best taken regularly rather than only when symptoms peak.

Intranasal corticosteroid sprays (fluticasone, budesonide, mometasone, beclomethasone) are the most effective medications available for allergic rhinitis. They reduce nasal inflammation through multiple pathways and are more effective than antihistamines for nasal congestion. Regular daily use produces better results than as-needed use, and full effects develop over a week or two of consistent use rather than immediately. Systemic absorption from intranasal sprays at recommended doses is minimal, making them safe for long-term use.

Leukotriene receptor antagonists (montelukast) block leukotriene-mediated inflammation and are used for both allergic rhinitis and asthma. They're generally less effective than intranasal corticosteroids for rhinitis symptoms but have a role in combined treatment and are useful for people who can't tolerate nasal sprays. The FDA added a black box warning in 2020 noting neuropsychiatric side effects including mood changes, depression, and suicidality in some patients — a consideration that's changed prescribing for mild-to-moderate cases.

Mast cell stabilizers (cromolyn sodium) prevent mast cells from releasing inflammatory mediators when triggered. They are most effective when taken before allergen exposure, require consistent use to work, and are very safe including for pregnancy and young children — but they are less potent than intranasal corticosteroids and have largely been supplanted by them for routine use.

Epinephrine (adrenaline) is the treatment for anaphylaxis — the severe, potentially life-threatening allergic reaction that causes airway swelling, cardiovascular collapse, and shock. It reverses the key mechanisms of anaphylaxis and must be given promptly. People with a history of serious allergic reactions are prescribed auto-injectors (EpiPen and equivalents) to carry at all times, and anyone who has had anaphylaxis remains at elevated risk of future severe reactions on re-exposure.

Allergen Immunotherapy: Changing the Underlying Response

Unlike medications that manage symptoms, allergen immunotherapy (AIT) aims to modify the immune response itself, reducing reactivity to allergens over time. It is the closest thing available to treating the cause of allergies rather than just the effects — and the evidence for its effectiveness in appropriate candidates is robust.

Subcutaneous immunotherapy (allergy shots) involves administering gradually increasing doses of allergen extract by injection, typically weekly during a buildup phase lasting several months, followed by maintenance injections every 2–4 weeks for 3–5 years. The process induces immune tolerance — shifting the immune response away from the IgE-driven allergic pattern — and produces sustained benefit that persists for years after completing treatment. Allergy shots are effective for allergic rhinitis (reducing symptoms by 30–40% more than medication alone), allergic asthma, insect venom allergy (where they provide up to 98% protection against systemic reactions), and certain occupational allergies.

Sublingual immunotherapy (SLIT) administers allergen extract as drops or tablets placed under the tongue. It avoids injections and can be administered at home, making it more convenient. FDA-approved sublingual tablet products exist for grass pollen, ragweed, house dust mite, and northern pasture grasses. The evidence base is stronger for tablet formulations than for sublingual drops, and the effect size is generally somewhat smaller than injection-based therapy, though meaningful.

Both forms of immunotherapy are most appropriate for people with moderate-to-severe symptoms that aren't adequately controlled by medications, for those who want to reduce long-term medication use, or for people with insect venom allergy where the stakes of a reaction are highest. The commitment to a multi-year treatment course is substantial, and immunotherapy is managed by allergists rather than primary care providers in most cases.

Biologics and Emerging Treatments

A newer class of treatments — biologic medications that target specific molecules in the allergic immune pathway — has expanded options for people with severe or difficult-to-control allergic conditions.

Omalizumab (Xolair) was the first anti-IgE biologic approved for allergic conditions. It binds circulating IgE, reducing the amount available to sensitize mast cells, and is used for moderate-to-severe allergic asthma inadequately controlled by standard treatments and for chronic idiopathic urticaria (hives). Omalizumab is administered by injection every 2–4 weeks and produces significant symptom and exacerbation reduction in appropriate patients. More recently it has also been approved for IgE-mediated food allergy — not to enable food consumption, but to raise the threshold for accidental exposure reactions in multi-food allergic patients.

Dupilumab (Dupixent) blocks the signaling of two key cytokines in the allergic pathway (IL-4 and IL-13) and is approved for severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Clinical trial results for atopic dermatitis have been particularly striking, with large proportions of patients achieving substantial skin clearance — outcomes that weren't achievable with previous treatments for severe disease.

Several other biologics targeting different points in the allergic signaling cascade (mepolizumab, benralizumab, tezepelumab for severe asthma; tralokinumab and lebrikizumab for atopic dermatitis) have expanded the treatment landscape further. These medications are expensive and require specialist management, but for patients with severe disease that wasn't previously manageable, they represent a meaningful advancement. The same evidence-based approach that helps evaluate supplement and lifestyle interventions — looking at mechanism, population studied, and actual clinical trial outcomes — is essential when considering these complex treatment decisions, just as it is for evaluating anti-inflammatory supplement claims or other health interventions.

Anaphylaxis: Recognizing and Responding to the Severe End

Anaphylaxis is a systemic, potentially life-threatening allergic reaction that occurs in 0.05–2% of the population at some point. It progresses rapidly, typically within minutes of exposure, and can involve multiple body systems simultaneously. Recognizing it quickly and responding appropriately is critical.

The defining feature of anaphylaxis is involvement of the cardiovascular or respiratory system — or both. Symptoms may include throat tightening and difficulty swallowing, hoarseness or stridor (high-pitched breathing sound), wheezing and bronchospasm, sudden drop in blood pressure, rapid weak pulse, loss of consciousness, and severe swelling of the tongue, lips, or throat. These often occur alongside skin symptoms (hives, flushing, swelling) and gastrointestinal symptoms (nausea, vomiting, cramping), but skin symptoms may be absent in up to 20% of anaphylaxis cases — their absence doesn't rule out the diagnosis.

Epinephrine injected into the outer thigh muscle is the first-line treatment and should be given immediately when anaphylaxis is suspected. Antihistamines and corticosteroids are secondary treatments and should never substitute for or delay epinephrine — they work too slowly to address the acute cardiovascular and respiratory components. After any anaphylaxis episode, emergency medical evaluation is essential even if symptoms seem to be resolving, because biphasic reactions (a second wave of symptoms occurring hours later without re-exposure) occur in up to 20% of cases.

For anyone who has had anaphylaxis, the management plan involves prescription epinephrine auto-injectors to carry at all times, a written emergency action plan, identification and avoidance of the trigger, and evaluation for allergen immunotherapy where it applies (particularly for insect venom allergy, which is one of the strongest indications for immunotherapy).

Prevention: What the Evidence Says About Early Exposure

One of the most significant shifts in allergy medicine in the past decade has been the reversal of guidance on food allergy prevention. For years, medical organizations recommended that high-risk infants delay introduction of allergenic foods — particularly peanuts — based on the assumption that earlier exposure increased allergy risk. This guidance was contradicted by the landmark LEAP (Learning Early About Peanut Allergy) trial published in 2015, which found that early introduction of peanuts in high-risk infants between 4 and 11 months of age reduced peanut allergy development by approximately 80% compared to avoidance.

This finding has since been supported by follow-up studies and translated into updated clinical guidelines: high-risk infants (those with severe eczema or egg allergy) are now recommended to receive early peanut introduction, ideally with allergist guidance. A 2025 analysis from Children's Hospital of Philadelphia found a 43% reduction in peanut allergy diagnoses in infants following revised early-introduction guidelines. The principle extends to other allergenic foods: the current evidence favors early, regular introduction of common allergens rather than delayed avoidance.

For inhalant allergens like pollen, dust mites, and pet dander, prevention is harder — avoidance reduces exposure but is rarely complete. Dust mite reduction measures (impermeable mattress and pillow covers, regular hot washing of bedding, reducing indoor humidity) show meaningful benefit in people with confirmed dust mite allergy. HEPA air filters can reduce indoor particulate allergen levels, though their clinical benefit in reducing symptoms is modest. Pet avoidance is the most effective pet allergy intervention, though rehoming a pet is obviously a significant decision that many people aren't willing or able to make.

For people without an existing allergy, environmental exposures in early childhood — growing up on farms, having dogs, spending time in diverse natural environments — appear to be protective against developing allergic conditions, consistent with the hygiene hypothesis and microbiome research. This suggests that appropriate outdoor exposure and microbiome-supportive diets rich in fiber may have long-term immunological benefits, connecting to the broader evidence for how foundational dietary habits affect immune function and inflammation, parallel to how nutrients like omega-3 fatty acids affect inflammation and immune signaling, as examined in the evidence on getting adequate EPA and DHA from diet.

Skin Involvement: Eczema, Hives, and Contact Reactions

Allergic conditions that primarily affect the skin represent a distinct but related set of presentations that deserve specific mention because they're often managed differently from respiratory and food allergies.

Atopic dermatitis (eczema) involves a combination of a defective skin barrier — due in part to mutations in the filaggrin gene that compromise the structural integrity of the outer skin layer — and immune dysregulation that drives chronic inflammation. The skin barrier defect allows allergens and irritants to penetrate more easily, sensitizing the immune system and perpetuating the cycle. Eczema management involves barrier repair through consistent moisturizing (particularly with ceramide-containing formulations that support the stratum corneum), avoiding known irritants and triggers, topical anti-inflammatory treatments (corticosteroids, calcineurin inhibitors like tacrolimus and pimecrolimus), and for severe disease, systemic treatments including biologics. The barrier function connection is shared with other skin conditions affected by inflammatory pathways, similar to how niacinamide supports barrier repair in skin care contexts — the same biological principle of maintaining stratum corneum integrity applies across contexts, as covered in the discussion of evidence-backed skincare ingredients.

Chronic urticaria (hives lasting more than six weeks) affects about 1–2% of people and can be profoundly disabling. Most chronic urticaria is "idiopathic" — without an identifiable external trigger — and involves autoimmune mechanisms in a significant proportion of cases (autoimmune chronic urticaria). It's treated with non-sedating antihistamines as first-line, often at doses higher than the standard labeling (up to fourfold), with omalizumab as an effective second-line option for cases unresponsive to antihistamines. Despite the name "urticaria," avoiding allergy triggers usually doesn't help because most chronic hives aren't triggered by external allergens.

Contact dermatitis — either allergic (immune-mediated, Type IV) or irritant (direct tissue damage without immune involvement) — presents as localized redness, itching, and blistering where the skin contacted the offending substance. Common allergens in contact dermatitis include nickel (in jewelry and belt buckles), fragrance chemicals, preservatives in personal care products, latex, and hair dye components. Patch testing identifies the specific culprit, and management centers on avoidance — there's no desensitization option equivalent to immunotherapy for IgE-mediated allergy.

When to See an Allergist

Many people with mild seasonal allergies or straightforward atopic conditions manage adequately with over-the-counter medications and self-care. But specialist evaluation by an allergist/immunologist offers significant value in several situations.

Anaphylaxis — whether a prior episode or ongoing risk — warrants allergist evaluation for proper trigger identification, prescription of epinephrine auto-injectors, and assessment for immunotherapy candidacy (particularly for venom allergy). Asthma that isn't well-controlled with standard medications, or asthma that may have a significant allergic component, benefits from allergist evaluation to identify triggers and assess biologic therapy eligibility. Food allergies where there's uncertainty about the diagnosis, about which specific foods to avoid, or about whether a childhood allergy has been outgrown benefit from specialist allergy testing and potentially supervised food challenges. Severe or significantly quality-of-life-impairing allergic rhinitis, atopic dermatitis, or hives that aren't responding to standard treatments are all situations where specialist management can substantially change outcomes. And anyone considering allergen immunotherapy requires allergist evaluation to determine candidacy, appropriate allergen selection, and monitoring during treatment.

The Bottom Line on Allergies

Allergies represent an immune system that is working — it's simply working on the wrong target. The IgE-mediated mechanism that drives most common allergic conditions is well understood, and it creates clear opportunities for intervention at multiple points: avoiding the trigger, blocking the mediators released, and modifying the immune response itself.

Treatment exists across a broad spectrum of effectiveness and commitment. Antihistamines and intranasal corticosteroids manage symptoms effectively for many people. Allergen immunotherapy addresses the underlying immune dysfunction and produces durable effects that outlast treatment. Biologics have transformed outcomes for people with severe atopic dermatitis, asthma, and other conditions that didn't respond to previous treatments. And for food allergy prevention, the reversal of guidance toward early introduction represents one of the clearest examples in recent medicine of evidence successfully changing practice in a way that measurably reduces disease.

The rising prevalence of allergies in industrialized societies is a genuine public health challenge without a simple fix, but understanding the immune mechanisms, recognizing when to seek specialist care, and using the evidence-based interventions available produces substantially better outcomes than either ignoring symptoms or over-medicating without addressing root causes. The same principle of understanding mechanisms — rather than just responding to symptoms — applies across health decisions, from allergies to the broader practices that support long-term wellbeing, as documented in the evidence on what actually drives meaningful biological health changes.